Pulmonx Q4 revenue $19.3M (+25% YoY); full-year 2023 revenue $68.7M (+28% YoY)

Pulmonx Corp

2023-FY EPS reported -$1.60 revenue$68,675,000

Record Q4 U.S. revenue of $13.7M (+45% YoY); added 14 new Zephyr Valve treatment centers.
Gross margin improved to 75% in Q4; full-year gross margin flat at 74%.
Net loss of $13.9M ($0.36/share) in Q4; full-year net loss $60.8M ($1.60/share).
Adjusted EBITDA loss narrowed to $39.0M in 2023 from $41.1M in 2022.
2024 revenue guidance of $81-84M; expects gross margin 74-75% and OpEx $132-134M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmonx Corp reported fourth quarter ended December 31, 2023 results: revenue $19.3 million, net income $13.9 million net loss, EPS -$0.36 per share.

Period: fourth quarter ended December 31, 2023
Revenue: $19.3 million
Net income: $13.9 million net loss
EPS: -$0.36 per share
Result: reported results

Exact text from the filing

Total worldwide revenue in the fourth quarter of 2023 was $19.3 million, a 25% increase from $15.4 million in the fourth quarter of 2022 and an increase of 23% on a constant currency basis.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmonx Corp reported full year 2024 results: revenue $81 million to $84 million. Guidance initiated.

Period: full year 2024
Revenue: $81 million to $84 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Pulmonx expects revenue for the full year 2024 to be in the range of $81 million to $84 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmonx Corp reported full year ended December 31, 2023 results: revenue $68.7 million, net income $60.8 million net loss, EPS -$1.60 per share.

Period: full year ended December 31, 2023
Revenue: $68.7 million
Net income: $60.8 million net loss
EPS: -$1.60 per share
Result: reported results

Exact text from the filing

Total worldwide revenue for the full year of 2023 was $68.7 million, a 28% increase from $53.7 million for the full year of 2022 and an increase of 28% on a constant currency basis.

View on SEC.gov

Browse all earnings releases →

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.